Cytokine-armed pyroptosis for cancer treatment
Inflammasomes play a critical role in immune defense by triggering the secretion of pro-inflammatory cytokines and inducing pyroptosis in infected cells. This dual action serves as a powerful mechanism against pathogenic microbes. Conversely, cancer cells have evolved numerous strategies to evade the immune system. Inspired by inflammasomes, researchers at the National Institute of Chemistry have developed a novel therapeutic strategy called cytokine-armed pyroptosis. This approach combines the local secretion of immunostimulatory cytokines from tumors with the immunogenic cell death of cancer cells.
In a mouse model of melanoma, inducing intratumoral pyroptosis alone led to complete remission in approximately 20% of the mice. Remarkably, when tumors were preconditioned to secrete immunostimulatory cytokines before pyroptosis, the cure rate increased to over 40%. However, the type of cytokine strongly influences the treatment outcome, some cytokines such as interleukin-12 boost the effect of pyroptosis, while others (such as interferon-γ) abort it. Furthermore, the study showed that animals cured through this approach developed resistance to the recurrence of the same type of tumor. This study demonstrates that short-term local inflammation leads to potent systemic antitumor immunity.ž
In the current study, therapeutic components were delivered via DNA electroporation, a method well-suited for accessible tumors such as skin cancers. Future research will focus on developing alternative delivery systems to enable the treatment of deep-seated tumors.
Authors of the study, published in the journal Nature Communications are: Sara Orehek, Taja Železnik Ramuta, Duško Lainšček, Špela Malenšek, Martin Šala, Mojca Benčina, Roman Jerala and Iva Hafner Bratkovič. Access link: https://doi.org/10.1038/s41467-024-55083-3
Sara Orehek will present the study on January 21 at Forum 40.
Kindly invited!
Contact: iva.hafner(at)ki.si


